Clinical Trial Update: A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase II randomized, double-blind study evaluating adjuvant pembrolizumab versus placebo in head and neck cancers at high…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: University of Chicago | Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: ACTIVE_NOT_RECRUITING